The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets
Open accessAbstract
The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such as air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such as arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can result in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic diseases like lupus and Sjogren’s syndrome. Severe disease in a subset of patients may be driven by cytokine storm, possibly due to secondary hemophagocytic lymphohistiocytosis (HLH), akin to that in systemic onset juvenile idiopathic arthritis or adult-onset Still’s disease. In the absence of high-quality evidence in this emerging disease, understanding of pathogenesis may help postulate potential therapies. Angiotensin converting enzyme 2 (ACE2) appears important for viral entry into pneumocytes; dysbalance in ACE2 as caused by ACE inhibitors or ibuprofen may predispose to severe disease. Preliminary evidence suggests potential benefit with chloroquine or hydroxychloroquine. Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored. Cytokine storm and secondary HLH might require heightened immunosuppressive regimens. Current international society recommendations suggest that patients with rheumatic diseases on immunosuppressive therapy should not stop glucocorticoids during COVID-19 infection, although minimum possible doses may be used. Disease-modifying drugs should be continued; cessation may be considered during infection episodes as per standard practices. Development of a vaccine may be the only effective long-term protection against this disease. Key Points • Patients with coronavirus disease 19 (COVID-19) may have features mimicking rheumatic diseases, such as arthralgias, acute interstitial pneumonia, myocarditis, leucopenia, lymphopenia, thrombocytopenia and cytokine storm with features akin to secondary hemophagocytic lymphohistiocytosis. • Although preliminary results may be encouraging, high-quality clinical trials are needed to better understand the role of drugs commonly used in rheumatology like hydroxychloroquine and tocilizumab in COVID-19. • Until further evidence emerges, it may be cautiously recommended to continue glucocorticoids and other disease-modifying antirheumatic drugs (DMARDs) in patients receiving these therapies, with discontinuation of DMARDs during infections as per standard practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
RetractedExperimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., Liao, X., Gu, Y., Cai, Q., Yang, Y., et al. (2020) · Engineering · doi:10.1016/j.eng.2020.03.007 · Cited by 1,357
RetractedClinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1
van Doremalen, N., Bushmaker, T., Morris, D. H., Holbrook, M. G., Gamble, A., Williamson, B. N., Tamin, A., Harcourt, J. L., Thornburg, N. J., Gerber, S. I., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2004973 · Cited by 9,951 · cited 1×
“Emerging evidence suggests that the virus spreads by droplets and fomites [54].”
BackgroundCOVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa248 · Cited by 4,775
Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., Ji, R., Wang, H., Wang, Y., & Zhou, Y. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.03.017 · Cited by 4,206
Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., & Shaman, J. (2020) · Science · doi:10.1126/science.abb3221 · Cited by 3,633
COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses
Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.03.005 · Cited by 3,536
Fair Allocation of Scarce Medical Resources in the Time of Covid-19
Emanuel, E. J., Persad, G., Upshur, R., Thome, B., Parker, M., Glickman, A., Zhang, C., Boyle, C., Smith, M., & Phillips, J. P. (2020) · New England Journal of Medicine · doi:10.1056/nejmsb2005114 · Cited by 3,137
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
Fang, L., Karakiulakis, G., & Roth, M. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30116-8 · Cited by 2,911
High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa
Xu, H., Zhong, L., Deng, J., Peng, J., Dan, H., Zeng, X., Li, T., & Chen, Q. (2020) · International Journal of Oral Science · doi:10.1038/s41368-020-0074-x · Cited by 2,838
Wilder-Smith, A., & Freedman, D. O. (2020) · Journal of Travel Medicine · doi:10.1093/jtm/taaa020 · Cited by 2,727 · cited 1×
“Controlling the infection by imposing severe restrictions on travel and social contacts can be viewed as the main strategy, primarily benefiting the elderly and those with chronic comorbid conditions [55].”
BackgroundEffective treatment of severe COVID-19 patients with tocilizumab
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,647
Gao, J., Tian, Z., & Yang, X. (2020) · BioScience Trends · doi:10.5582/bst.2020.01047 · Cited by 2,590
Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)
Gomes, C. A. (2020) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 2,134
Grant, W., Lahore, H., McDonnell, S., Baggerly, C., French, C., Aliano, J., & Bhattoa, H. (2020) · Nutrients · doi:10.3390/nu12040988 · Cited by 2,066
Driggin, E., Madhavan, M. V., Bikdeli, B., Chuich, T., Laracy, J., Biondi-Zoccai, G., Brown, T. S., Der Nigoghossian, C., Zidar, D. A., Haythe, J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.031 · Cited by 2,017
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
Russell, C. D., Millar, J. E., & Baillie, J. K. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30317-2 · Cited by 2,008
COVID-19 and cardiovascular disease
Clerkin, K. J., Fried, J. A., Raikhelkar, J., Sayer, G., Griffin, J. M., Masoumi, A., Jain, S. S., Burkhoff, D., Kumaraiah, D., Rabbani, L., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046941 · Cited by 1,738
Lippi, G., Plebani, M., & Henry, B. M. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.03.022 · Cited by 1,706
Prolonged presence of SARS-CoV-2 viral RNA in faecal samples
Wu, Y., Guo, C., Tang, L., Hong, Z., Zhou, J., Dong, X., Yin, H., Xiao, Q., Tang, Y., Qu, X., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30083-2 · Cited by 1,547
Mechanisms of action of hydroxychloroquine and chloroquine:implications for rheumatology
Schrezenmeier, E., & Dörner, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0372-x · Cited by 1,468
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30304-4 · Cited by 1,456
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
Dong, L., Hu, S., & Gao, J. (2020) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2020.01012 · Cited by 1,390
Real estimates of mortality following COVID-19 infection
Baud, D., Qi, X., Nielsen-Saines, K., Musso, D., Pomar, L., & Favre, G. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30195-x · Cited by 1,253
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav, S. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.03.005 · Cited by 1,160
Liu, W., Tao, Z.-W., Wang, L., Yuan, M.-L., Liu, K., Zhou, L., Wei, S., Deng, Y., Liu, J., Liu, H.-G., et al. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000775 · Cited by 1,104
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Colson, P., Rolain, J.-M., Lagier, J.-C., Brouqui, P., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105932 · Cited by 937 · cited 1×
“Preliminary reports suggest that chloroquine and hydroxychloroquine are probably equally beneficial in COVID-19 and that a loading dose of the drug should be followed by a maintenance dose, prescribed for a long period [35].”
EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies
Ramos-Casals, M., Brito-Zerón, P., Bombardieri, S., Bootsma, H., De Vita, S., Dörner, T., Fisher, B. A., Gottenberg, J.-E., Hernandez-Molina, G., Kocher, A., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216114 · Cited by 732
Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin
Hu, H., Ma, F., Wei, X., & Fang, Y. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa190 · Cited by 687
Lim, J., Jeon, S., Shin, H.-Y., Kim, M. J., Seong, Y. M., Lee, W. J., Choe, K.-W., Kang, Y. M., Lee, B., & Park, S.-J. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e79 · Cited by 636
Sex difference and smoking predisposition in patients with COVID-19
Cai, H. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30117-x · Cited by 625
Chloroquine for the 2019 novel coronavirus SARS-CoV-2
Colson, P., Rolain, J.-M., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105923 · Cited by 468
Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
Batlle, D., Wysocki, J., & Satchell, K. (2020) · Clinical Science · doi:10.1042/cs20200163 · Cited by 444
Kim, J. Y., Choe, P. G., Oh, Y., Oh, K. J., Kim, J., Park, S. J., Park, J. H., Na, H. K., & Oh, M.-D. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e61 · Cited by 404
Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists
Day, M. (2020) · BMJ · doi:10.1136/bmj.m1086 · Cited by 397
Covid-19 — The Search for Effective Therapy
Baden, L. R., & Rubin, E. J. (2020) · New England Journal of Medicine · doi:10.1056/nejme2005477 · Cited by 320
The Novel Coronavirus: A Bird's Eye View
Habibzadeh, P., & Stoneman, E. K. (2020) · The International Journal of Occupational and Environmental Medicine · doi:10.15171/ijoem.2020.1921 · Cited by 307
Fan, H.-H., Wang, L.-Q., Liu, W.-L., An, X.-P., Liu, Z.-D., He, X.-Q., Song, L.-H., & Tong, Y.-G. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000797 · Cited by 304
Andreasen, V., Viboud, C., & Simonsen, L. (2008) · The Journal of Infectious Diseases · doi:10.1086/524065 · Cited by 239
Kwon, K. T., Ko, J.-H., Shin, H., Sung, M., & Kim, J. Y. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e123 · Cited by 238
The antiviral properties of vitamin C
Colunga Biancatelli, R. M. L., Berrill, M., & Marik, P. E. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1706483 · Cited by 189
Gonçalves-Mendes, N., Talvas, J., Dualé, C., Guttmann, A., Corbin, V., Marceau, G., Sapin, V., Brachet, P., Evrard, B., Laurichesse, H., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00065 · Cited by 146
Grant, W. B., Anouti, F. A., & Moukayed, M. (2020) · European Journal of Clinical Nutrition · doi:10.1038/s41430-020-0564-0 · Cited by 80
Covid-19: European drugs agency to review safety of ibuprofen
Day, M. J. (2020) · BMJ · doi:10.1136/bmj.m1168 · Cited by 76
Antimicrobials and QT prolongation
Mason, J. W. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw591 · Cited by 67
Hindawi, S., Hashem, A. M., Damanhouri, G. A., El-Kafrawy, S. A., Tolah, A. M., Hassan, A. M., & Azhar, E. I. (2017) · Transfusion · doi:10.1111/trf.14422 · Cited by 48
Cited by
A Review of Persistent Post-COVID Syndrome (PPCS)
Oronsky, B., Larson, C., Hammond, T. C., Oronsky, A., Kesari, S., Lybeck, M., & Reid, T. R. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08848-3 · Cited by 422
Rabaan, A. A., Al-Ahmed, S. H., Muhammad, J., Khan, A., Sule, A. A., Tirupathi, R., Mutair, A. A., Alhumaid, S., Al-Omari, A., Dhawan, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9050436 · Cited by 255
Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad
Ahmed, S., Zimba, O., & Gasparyan, A. Y. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05275-1 · Cited by 251
Self-citation
Metadata
- Authors
- Misra, D. P., Agarwal, V., Gasparyan, A. Y., & Zimba, O.
- Venue
- Clinical Rheumatology
- Published
- 2020-04-10
- Volume
- 39
- Issue
- 7
- Pages
- 2055-2062
- ISSN
- 0770-3198 (ISSN-L)
- 1434-9949
- OpenAlex
- W3015542196
- Cited by
- 271
- References
- 51
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.